Innovative Medicine

Data show the vaccine regimen induced neutralizing antibody responses in nearly all participating adults and children 21 days after the second dose Adults receiving booster shots two years after initial vaccination regimen showed strong immune responses The data support the potential prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect adults and children

Data for approved and investigational treatments to be presented in bladder cancer, lung cancer and prostate cancer Investigational RYBREVANT® (amivantamab-vmjw) and lazertinib combination therapy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to be featured in oral presentations

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines

The Women in STEM2D (WiSTEM2D) Scholars Award honors female scholars with $150,000 grant and three years of mentorship Deadline for applications is Sept. 27, 2021

XARELTO® is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, now including PAD patients post-LER XARELTO® is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation PAD impacts 20 million Americans1 and is the leading cause of amputations in the U.S., with rates continuing to rise2

New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy

55.2 percent of patients were in symptomatic remission and 96.4 percent of patients were corticosteroid-free at week 152 New data from the UNIFI study is one of 22 Janssen abstracts, including five oral and three digital oral presentations, at the 16th Congress of the European Crohn’s and Colitis Organisation

J&J Centers for Global Health Discovery (J&J Centers) are a new cornerstone of the Company’s efforts to solve the world’s most pressing health challenges The first J&J Satellite Center is hosted at the London School of Hygiene & Tropical Medicine (LSHTM) and focused on addressing the threat of antimicrobial resistance and tuberculosis J&J Centers will include collaborations with renowned academic institutions that accelerate potentially lifesaving innovations from the lab to the last mile

Application seeks two pediatric indications, including an age-appropriate new weight-based oral suspension formulation to help minimize dosing errors If approved, XARELTO® will be the first and only oral Factor Xa inhibitor indicated in the U.S. for use in appropriate pediatric patients